# Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

> **NCT07432100** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Mingfeng Zhao** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Chimeric Antigen Receptor T-cell
- Universal CLL1 CAR-T

## Interventions

- **BIOLOGICAL:** universal CLL1 CAR-T cells

## Key facts

- **NCT ID:** NCT07432100
- **Lead sponsor:** Mingfeng Zhao
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2028-12
- **Final completion:** 2028-12-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432100, "Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07432100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*